Novo Nordisk, a global leader in diabetes care today announced the launch of Ryzodeg in Malaysia, a co-formulation insulin treatment made from a 70:30 ratio of two types of distinct insulins – insulin degludec and insulin aspart that helps maintain stable control of glucose levels.

This co-formulation without the need of resuspension provides 24-hour coverage which results in better fasting plasma glucose and better control for one or two meal-related glucose excursions.

“At Novo Nordisk, we are dedicated to developing treatments that are available for the millions
of Malaysians living with diabetes.

“We hope this innovation derived from the combined benefits of insulin degludec and insulin aspart will pave the way for diabetes care and management in Malaysia as an effective treatment alternative for the patients,” said Novo Nordisk Malaysia, Singapore and Brunei, vice president and general manager, Richard Abela.

This prescription-based insulin can be delivered as once-daily or twice-daily injection in a new
prefilled insulin pen called FlexTouch with no need for resuspension, providing Malaysians living with diabetes a smart treatment alternative.

“With Ryzodeg now available in the market, this innovative, simple, and smart diabetes treatment will enable more effective diabetes care and management, providing patients with a more positive treatment journey that will also improve their everyday life,” said Consultant Endocrinologist, Dr Chan Siew Pheng,

Twitter